Why Pfizer Stock Is Sinking Today
Shares of (NYSE: PFE) were sinking 4.4% lower as of 11:10 a.m. ET on Friday after falling as much as 7.1% earlier in the morning. The sell-off came after the company announced that it's throwing in the towel on a twice-daily version of experimental weight-loss pill danuglipron.
Pfizer made the decision based on results from a phase 2b clinical study of danuglipron. This study achieved its primary endpoint, with patients experiencing placebo-adjusted weight loss between 5% and 9% at 26 weeks and between 8% and 13% at 32 weeks. However, there were high rates of side effects (up to 73% of patients experienced nausea and up to 47% experienced vomiting). Discontinuation rates were also very high -- above 50%.
There was simply no way that Pfizer could advance the twice-daily version of danuglipron into phase 3 testing with the dismal adverse event and discontinuation numbers. But how bad was this news for Pfizer? Pretty bad.
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 28.13 € bedeuten.